. 2021 Oct 23;13(2):517–540. doi: 10.1016/j.jcmgh.2021.10.008

Table 2.

Chromosomal Segment Copy Number Alterations Between Drug-Tolerant CT–PDTOs and Their Drug-Sensitive Parental PDTOs

Position	NumExons	Size, bp	Amplification score
CT-PDTO1 vs PDTO1
chr1:69085-12939931	1817	12,870,846	1.43^a
chr3:361455-54922084	4830	54,560,629	0.68^b
chr3:54925377-93754285	980	38,828,908	0.60^b
chr11:193095-50004042	3797	49,805,878	1.55^a
chr11:51411443-134257558	7159	82,846,115	0.70^b
chrY:150850-5605988	134	5,408,963	2.28^a
CT-PDTO2 vs PDTO2
chr3:67048775-123689069	1880	56,640,294	0.68^b
chr3:129291447-197896728	3682	68,605,281	0.71^b
chr4:9828016-191013439	6594	181,185,423	0.68^b
chr8:30854104-43048991	698	12,194,887	0.60^b
chr8:43052086-75272550	1009	32,220,464	0.42^b
chr8:75274114-116430685	1408	41,156,571	0.34^b
chr8:116599223-146279548	1803	29,680,325	0.44^b
chr18:158694-14764094	802	14,605,400	3.12^a
chr18:14769337-25593878	463	10,824,541	2.54^a
chr18:25727632-35145609	430	9,412,412	1.69^a
chr18:39535252-78005236	1321	38,469,984	0.52^b
chr20:36940271-62904958	2202	25,959,983	0.64^b
CT-PDTO5 vs PDTO5
chr1:69085-207318067	17,379	207,211,337	0.69^b
chr1:207495106-236445088	1987	28,872,632	0.69^b
chr1:236557740-249212567	685	12,654,827	0.69^b
chr3:361455-127317320	7650	126,904,466	0.52^b
chr3:127318156-197896728	3946	70,578,572	0.52^b
chr13:28562595-53035114	1406	24,469,320	0.71^b
chr22:24621509-45122519	2420	20,501,010	0.71^b

NOTE. Relative copy number alterations after FOLFIRI/Cmab adaptation were detected by whole-exome sequencing on genomic DNA derived from the indicated tumor organoid cultures. Chromosomal boundaries of altered segments are indicated (Position, reference genome hg19). The cut-off value for amplified and deleted regions is ± 1.4-fold, as shown in the Amplification Score column.

NumExons, total number of exons located on the chromosomal segment affected by relative copy number alteration; Size, number of nucleotides affected by the respective chromosomal segment alteration.

Amplified.

Deleted.